Back to search results

REMAP-CAP Study for Severe Pneumonia, Influenza, and COVID-19

This study, called REMAP-CAP, is looking for adults who are in the intensive care unit (ICU) with severe community-acquired pneumonia (a lung infection caught outside of a hospital). It aims to find the best treatments for this condition, including for influenza and COVID-19. Researchers are testing several commonly used antibiotics like Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline (this part of the study is now closed), and Amoxicillin-clavulanate. The study will measure how many people survive after 90 days and how many days people are alive and don't need organ support in the ICU after 21 days. The study is designed to help doctors understand which treatments work best for patients like you.

Study design
This is a randomized, embedded, multifactorial adaptive platform trial, meaning it can test multiple treatments at once and adjust based on early results. It plans to enroll up to 20,000 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study measures outcomes up to 90 days after treatment, specifically looking at survival and the need for organ support in the ICU.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02735707

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
PHASE3Ages 18+InterventionalTreatment
UMC Utrecht
~20,000 participants
Updated 2024-07-12 on ClinicalTrials.gov
What's tested:CeftriaxoneMoxifloxacin or LevofloxacinPiperacillin-tazobactamCeftarolineAmoxicillin-clavulanateStandard course macrolide

At a glance

Recruiting sites
234 of 408 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
All-cause mortality
Measured over Day 90
+1 more outcome measured

Conditions

Community-acquired Pneumonia, Influenza, COVID-19

Explore related trials

Community-Acquired PneumoniaCOVID-19 InfectionInfluenza

Where it's being run

408 sites across 58 states
England116
France24
New South Wales19
Netherlands19
Ontario17
Germany17
United Kingdom16
Victoria15

Study leadership

  • Steve Webb, Prof · STUDY_CHAIR · Monash University, Study Chair REMAP-CAP Australia
  • Colin McArthur, Dr · STUDY_CHAIR · Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand
  • Marc Bonten, Prof · STUDY_CHAIR · UMC Utrecht, Study Chair REMAP-CAP Europe
  • Lennie Derde, MD · STUDY_CHAIR · UMC Utrecht, Coordinating Investigator REMAP-CAP Europe
  • John Marshall, Prof · STUDY_CHAIR · Unity Health Toronto, Study Chair REMAP-CAP Canada
  • Derek Angus, Prof · STUDY_CHAIR · University of Pittsburgh Medical Center, Study Chair REMAP-CAP USA

Who to contact

Cameron Green, MSc
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • All-cause mortalityDay 90
  • Days alive and not receiving organ support in ICUDay 21

    Primary end-point for patients with suspected or proven COVID-19 pandemic infection